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Abstract
Bipolar disorder prevalence rates vary in the older adult population (defined as age ≥ 65 years), ranging from 1% in community dwellers to as high as 8–10% in hospital inpatients. Although older agents, including lithium and valproic acid, offer
significant antimanic efficacy, as supported by a recent randomized controlled trial (RCT), there is growing interest in using
atypical antipsychotics to treat bipolar disorder in older adults. Newer atypical antipsychotics are of interest based on their
tolerability and efficacy in the general adult bipolar population. The aim of this review was to systematically examine efficacy
and tolerability of newer atypical antipsychotics for older adult bipolar disorder (OABD). We conducted a systematic search
utilizing the MEDLINE, EMBASE, PsycINFO and Cochrane Library electronic databases, with the aim of identifying all
RCTs comparing newer atypical antipsychotics approved by the US FDA since 2002 (including brexpiprazole, cariprazine,
lurasidone, iloperidone, asenapine, paliperidone, and aripiprazole) with placebo or another comparator, in the treatment of any
phase of bipolar disorder (including mania, depression or mixed episodes while used as an acute or maintenance treatment)
in older adults (> 65 years). We found no RCT data on any of the examined agents. Hence, we changed our search criteria
to include studies with a lower age cut-off (≥ 55 years), as well as the inclusion of post hoc studies. Two post hoc studies on
lurasidone suggest its reasonable safety and efficacy profile in the acute and maintenance treatment of OABD; however, there
are no pharmacoeconomic data on the use of lurasidone in the treatment of OABD. Research data from open-label studies
on oral asenapine and aripiprazole as add-on therapy suggest that these two agents are adequately tolerated and improved
symptoms of depression and mania in OABD; hence, there is an urgent need to conduct RCTs on these two agents. Lastly,
we found no studies for the treatment of OABD with brexpiprazole, cariprazine, iloperidone, or paliperidone.
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Lithium and valproic acid remain the gold-standard
agents for the treatment of bipolar disorder, but they are
often not well tolerated in the older adult bipolar disorder (OABD) population. Newer atypical antipsychotics
are of interest, based on some efficacy in the general
adult population.
No randomized controlled data are available on brexpiprazole, cariprazine, lurasidone, iloperidone, asenapine, or aripiprazole in the treatment of OABD.
Post hoc data suggest lurasidone to be effective and well
tolerated in OABD.
Randomized controlled studies of newer atypical antipsychotics in OABD are urgently required.
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1 Introduction
Evidence suggests the prevalence rates of older adult
bipolar disorder (OABD) range from 1% in communitydwelling seniors to as many as 8–10% of geriatric inpatient
admissions and 17% of geriatric psychiatry emergency visits [1]. With a successfully aging society across the world,
it is predicted that the population of those above 60 years
of age will grow 3.5 times more rapidly than the rest of the
population [2]. With overall improvement in health care,
patients suffering from bipolar disorder are expected to
live longer into their late life. This will inevitably lead to
greater socioeconomic burden on the healthcare system, in
addition to a greater proportion of individuals with OABD
presenting to the primary care physician’s office and the
emergency room, as well as accessing psychiatric services.
Optimal management of bipolar disorder requires both
acute and maintenance treatment. Current guidelines
endorse the use of lithium as the prototypical mood stabilizer, and/or the antiepileptic valproic acid, along with
antipsychotics, as augmenting agents to stabilize mood
and/or manage agitation in the acute phase, as well as continuation of some of these agents in the maintenance phase
[3, 4]. Guidelines also recommend using antidepressants
in combination with a mood stabilizer for acutely treating depressive symptoms. While one of these guidelines
does offer some insight into the management of OABD
[4], it does not offer a detailed review of the safety and
efficacy of newer atypical antipsychotics for the treatment
of OABD.
Current literature guided the first international task
force on the treatment of late-life bipolar disorder [2] to
recognize an upcoming epidemic of the older-aged bipolar
cohort. It also acknowledged the need for a specific treatment approach for this population compared with the adult
patient with bipolar disorder. The effects of aging per se
lead to comorbidity with other physical illnesses such as
cardiovascular disease [5, 6], cerebrovascular disease [7],
diabetes mellitus, cancer [8], neurological conditions [9],
and premature mortality from general medical conditions
[10]. These illnesses require treatment with additional
medications, which increases the risk of drug interactions
and adverse effects [11]. Additionally, there are pharmacokinetic changes in drug metabolism due to age-related
reduction in renal clearance, increased risk of drug sensitivity to drugs acting on the central nervous system [12,
13], and cognitive decline associated with aging [14].
Other consensus guidelines recognize these biological factors and recommend using lower doses of all psychotropics
in the older-age bipolar patient [3].
The clinical management of OABD continues to be
largely based on expert consensus and extrapolated from
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studies of the general adult bipolar population [15–18].
The first large randomized controlled trial (RCT) on the
management of acute mania in late-life bipolar disorder
patients, the GERI-BD study, has recently been published
[19]. Findings indicated a significant improvement in
mania scores with lithium compared with valproate in the
early stages of acute treatment [19]; however, there was
no significant difference in response rates between the two
arms [19].
Over the last 15 years, newer atypical antipsychotics,
such as lurasidone, aripiprazole, asenapine, and cariprazine, have been approved by the US FDA for the treatment
of schizophrenia. Additionally, some of these agents have
been approved for the treatment of the acute and/or maintenance phase of bipolar illness in the general adult population, while some have also been approved for use in the child
and adolescent bipolar population; however, none of these
agents are currently approved for the treatment of OABD.
Theoretically, these agents might offer similar efficacy rates
compared with the general adult population; however, there
are no published reviews evaluating the safety or efficacy of
these agents in the OABD population. Safety concerns of
these agents include extrapyramidal side effects related to
dopamine receptor (D2) blockade (e.g. aripiprazole and brexipiprazole) and potential metabolic side effects. Therefore,
we aimed to review the safety and efficacy of these newer
atypical antipsychotics in the management of the OABD.
Such a review will hopefully better inform the treating clinician, as well as inform the therapeutic potential of these
agents in this growing and difficult-to-manage population.
We searched all related bipolar disorder terms in the
Ovid MEDLINE (In-Process and Other Non-Indexed
Citations, Ovid MEDLINE Daily and Ovid MEDLINE),
EMBASE (EMBASE Classic and EMBASE), PsycINFO,
and the Cochrane Library/EBM Reviews electronic databases. Search duration was from database inception to 7
April 2017. We specifically included the following atypical
antipsychotics that have been approved by the FDA since
2002: brexpiprazole, cariprazine, lurasidone, iloperidone,
asenapine, paliperidone, and aripiprazole. Filters for patients
aged ≥ 65 years, and RCTs, were added. To identify any currently ongoing or yet-to-be-published studies, we searched
the ClinicalTrials.gov registry database, as well as relevant
psychiatry conferences, for related abstracts over the last
5 years. Our outcome criteria included change in mood
scores and proportion of participants achieving a priori criteria of remission or response (e.g. 50% fall in a mania or
depression rating scale), while secondary outcomes were
rate of inpatient admission and readmission, change in function, quality of life, metabolic side effects, and response on
comorbid psychiatric symptoms such as anxiety.
Using these approaches, we were not able to identify
any RCTs conducted of these agents in OABD. When
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subsequently expanding our search to post hoc studies
assessing data from previous RCTs with a reduced age
threshold of ≥ 55 years, we identified two post hoc studies
of lurasidone in the treatment of late-life bipolar disorder.
Details of the findings of these studies, as well as a description of the pharmacological profile, safety, and efficacy data
from non-RCT design studies conducted on the other atypical antipsychotics, are provided below. In addition, we offer
recommendations on the use of each agent in OABD based
on such data.

2 Newer Atypical Antipsychotics for Older
Adult Bipolar Disorder
The mood stabilizers lithium and valproic acid have been the
mainstay of bipolar management across all age groups for at
least the last 30 years [20]. It is well known that while lithium has an excellent antimanic, antidepressant and antisuicidal effect, it suffers from a very narrow therapeutic index
[20]. Valproic acid also offers good antimanic effect, but its
use needs to be regularly monitored for risk of bone marrow
suppression, hepatotoxicity, hyperammonemia and encephalopathy [21–23]. With advancing age, older adults experience physiological changes that affect drug pharmacokinetics, including changes in drug distribution, metabolism, and
excretion [24]. The impact of reduction in total body water
composition, reduced glomerular filtration rate, and reduced
hepatic function in older adults further narrows the therapeutic index for lithium and valproic acid derivatives [25,
24]. In addition, older adults tend to be more sensitive to the
pharmacodynamic effects of all drugs [24, 26]. They also
tend to have more comorbidities, leading to increased risk of
drug–drug interactions and drug–disease interactions [11].
Research shows that over the last few years there has been
an explosion of data on the use of newer atypical antipsychotics in the treatment of bipolar disorder across the age
span. Besides their efficacy potential, such agents demonstrate a relatively wider therapeutic index compared with
lithium or valproate.

2.1 Brexpiprazole
Brexpiprazole is the most recently approved agent, approved
by the FDA in 2015 for the treatment of schizophrenia and as
an adjunctive therapy for the treatment of major depressive
disorder. Like other atypical antipsychotics, brexpiprazole
is a serotonin-dopamine neurotransmitter modulator [27]. It
differs from other agents by being a partial agonist at 5-HT1A
and dopamine D
 2 receptors, and is an antagonist a serotonin
5-HT2A and a drenergicα1B/2C receptors [27]. In vitro, brexpiprazole exhibits more D2 blockade than aripiprazole. It is
well absorbed, is metabolized by cytochrome P450 (CYP)

2D6 and CYP3A4, and has a long half-life of 91 h [28].
Dosing considerations in the elderly include manufacturerrecommended dose adjustments for concurrent CYP2D6 or
3A4 inhibition [28]. In addition, a recommended reduction
of maximum daily dose from 4 to 3 mg/day is suggested
in the setting of moderate to severe hepatic dysfunction or
moderate to severe end-stage renal disease [28]. There were
no clinically relevant effects on the ECG QT interval, as well
as minimal changes on serum prolactin levels [28].
There is currently an ongoing trial (NCT03259555)
assessing the safety and tolerability of brexpiprazole in
adults with bipolar mania with or without mixed episodes.
Although the tolerance and safety of this agent has not been
assessed in adults with bipolar disorder, some of the safety
aspects have been studied in schizophrenia. Akathisia (5.8%)
and weight gain (4.7%) were reported in a study of 1256
patients taking brexpiprazole 6 mg/day compared with placebo [29]. A newly diagnosed metabolic syndrome was also
more common compared with placebo (1.2% vs. 0.8%) in
the short-term, and even higher (3.1%) in longer-term trials
[29]. Brexpiprazole did not increase the QT interval in the
trials [29].
We suspect that due to the recent marketing approval of
brexpiprazole (2015), no data are as yet available regarding
either the safety or efficacy of this agent in adult or late-life
bipolar disorder.
While the pharmacological profile of this agent is somewhat unique, including activity on multiple receptor targets
associated with bipolar disorder and a long half-life, which
could offer benefits for patients unable to maintain drug
adherence, the lack of any data on OABD prevents us from
offering any recommendations of its use in this indication.

2.2 Cariprazine
Cariprazine was also approved in 2015 for the treatment
of schizophrenia and acute bipolar disorder. Its pharmacological profile includes being a D2 partial agonist, similar to
aripiprazole [30]. It also exhibits a dose-dependent preference for occupying D3 receptors at low doses, with increasing occupation of D2 receptors as the dose increases [30].
In addition, it displays 5-HT1A agonism effects [31, 30].
Cariprazine is metabolized by CYP3A4, and the manufacturer recommends a 50% dose reduction when coadministered with a strong CYP3A4 inhibitor such as ketoconazole
[31, 30]. Furthermore, cariprazine also has a long half-life
of 48–96 h, while its active metabolite, didesmethyl cariprazine, exhibits a half-life of 1–3 weeks [31, 30]. This could
manifest as a theoretical lack of an acute response and/
or management of agitation in the first few weeks of dose
titration [31, 30]. It is also recommended that cariprazine
be started at a lower dose and titrated much slower in the
elderly due to the risk of orthostatic hypotension [31, 30].
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Cariprazine has been evaluated in adults with bipolar manic or mixed episodes. In a phase II trial, patients
aged 18–65 years treated with cariprazine 3–12 mg/day
demonstrated significant improvement in manic symptoms
using the Young Mania Rating Scale (YMRS), in addition
to improvements on the Clinical Global Impression (CGI)
scale [32]. However, patients taking cariprazine experienced
more instances of akathisia (22%, vs. 6% with placebo)
and parkinsonism (16% vs. 1%) [32]. In another phase III
trial of patients aged 18–65 years, the efficacy of low-dose
(3–6 mg/day) cariprazine was similar to that of high-dose
cariprazine (6–12 mg/day) [33]. The most common adverse
effects from these studies include akathisia, parkinsonism,
and other extrapyramidal symptoms (EPS; 9.6% and 11.2%
at doses of 3–6 mg and 6–12 mg, respectively), which was
almost twice the placebo rates (5.6%) [33]. Other common
adverse effects were constipation (4.8% and 10.7% at doses
of 3–6 mg and 6–12 mg, respectively) compared with placebo (2.5%) [32]. Commonly reported adverse effects with
other atypical antipsychotics, such as weight gain, metabolic
disturbances, changes on ECG, or elevated prolactin have, to
date, not been reported with cariprazine [34, 35].
We found both an ongoing trial and a recently completed
trial assessing the efficacy and tolerability of this agent in
bipolar depression (NCT02670538, NCT01396447). However, at the time of this publication, no study results were
available on the safety and efficacy of cariprazine in OABD.
and hence there is insufficient data to recommend its use.

2.3 Lurasidone
Lurasidone was approved by the FDA in 2013 for the monotherapy treatment of bipolar depression [36]. It exhibits
high affinity as well as strong antagonism at D2, 5-HT2a,
and 5-HT7 receptors [37]. It also acts as a partial agonist
at the 5-HT1a receptors. These effects could be of benefit
in controlling comorbid anxiety [37]. Additionally, it is a
muscarinic and histaminergic receptor-sparing agent [37],
which could theoretically offer better tolerability in the
older aged population due to concerns of cognitive impairment with drugs that block such receptors. Lurasidone is
primarily metabolized by CYP3A4, and hence it should be
cautiously coadministered with inducers or inhibitors of
CYP3A4 [38]. The half-life of lurasidone is 18 h, which
provides simplicity in once-daily dosing [37, 38]. The drug
information approved by the FDA suggests starting lurasidone at a 40 mg once-daily dose and with slow titration until
therapeutic response or lack of tolerability, with a maximum
recommended daily dose of 160 mg [39]. This medication
should always be consumed with a meal containing at least
350 calories [39].
A post hoc analysis of an older adult cohort was
conducted on data from two previous double-blind,
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placebo-controlled studies of lurasidone in the acute
treatment of adult bipolar depression [40]. This post hoc
analysis specifically evaluated the efficacy and safety
of lurasidone in a late-life bipolar depression sample
(n = 142, age > 55 years). Lurasidone was administered
at 20–120 mg/day, either as monotherapy or adjunctive
therapy to either lithium or valproate [40]. In the monotherapy group, a mean change at week 6 on the Montgomery–Asberg Depression Rating Scale (MADRS) was
significantly greater for lurasidone versus placebo (− 14.8
vs. − 7.1; p = 0.003; effect size 0.83; pooled doses), while
in the adjunctive therapy group, mean change in MADRS
scores in the lurasidone group was not significantly different from the placebo group (− 13.9 vs. − 11.1; p = 0.398;
effect size 0.26) [40]. Lurasidone was found to be safe and
well-tolerated, as evidenced by reasonably low discontinuation rates in both the monotherapy and adjunctive therapy
studies (< 7.1%) [40]. Additionally, there were minimal
effects on metabolic laboratory values [40].
The same research group [41] also conducted a post
hoc analysis of a 6-month open-label extension maintenance study of lurasidone in 141 older adults as either
monotherapy or augmentation therapy. Patients were aged
55–75 years and had previously completed 6 weeks of a
double-blind, placebo-controlled treatment with either lurasidone 20–120 mg/day monotherapy, or augmentation with
lithium or valproate [41]. There was minimum increase in
weight (− 1.0 kg and − 0.4 kg, monotherapy or augmentation, respectively); total cholesterol (− 2.0 mg/dL and
+ 6.0 md/dL, respectively), triglycerides (+ 2.5 mg/dL and
+ 6.0 mg/dL, respectively), and HbA1c (0.0% and − 0.1%,
respectively) [41]. Adverse events occurring at any time in
the 6-month open-label phase were as follows for the monotherapy and adjunctive therapy groups: headache (14.5%,
10.5%), nasopharyngitis (10.9%, 4.7%), fatigue (9.1%,
3.5%), insomnia (7.3%, 11.6%), anxiety (7.3%, 7.0%), and
depression (7.3%, 4.7%). The rates of extrapyramidal side
effects were reported for akathisia (3.6%, 11.6%), tremor
(1.8%, 8.1%), and parkinsonism (3.6%, 7.0%) [41]. No clinically meaningful treatment-emergent changes were observed
in vital signs, ECG parameters, or blood chemistries during
this time [41]. One male and one female in the monotherapy
group (and none in the adjunctive therapy group) had a clinically significant increase in prolactin levels [41]. There was
a significant fall in MADRS scores in both the monotherapy
(− 6.2) and adjunctive therapy (− 6.7) groups [41].
The above data suggest that lurasidone offers significant potential to control depressive symptoms in both the
acute and maintenance phases of OABD. The lack of serious adverse events and overall metabolic safety suggests its
potential role for clinical use in OABD. Data on the pharmacoeconomic benefits, as well as the long-term effects on cardiovascular and cerebrovascular parameters, are still needed.
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2.4 Iloperidone

2.5 Asenapine

Iloperidone was approved by the FDA in 2009 for the
treatment of schizophrenia. It has an oral bioavailability
of 96% and does not require any caloric supplementation,
unlike lurasidone [42]. The effective dose range has been
estimated to be between 12 and 24 mg/day [42, 43]. It is
suggested that the dose be slowly titrated from 1 mg twice
daily, by doubling the dosage daily to avoid orthostatic
hypotension [42, 43]. Iloperidone demonstrates high binding affinity for D2 and D3 receptors, α1-adrenergic receptors, and 5-HT 2A [42]; however, receptor affinity for D2
and 5-HT2A, is low compared with other antipsychotics
such as lurasidone and asenapine [44]. Iloperidone demonstrates moderate affinity for α2 receptors, and therefore
may have greater risk of orthostatic hypotension [45, 46].
It also shows mild antagonism on 5-HT1A receptors [44].
Finally, it exhibits minimal affinity for H1 receptors, thus
theoretically offering limited sedation and weight gain
[46]. Iloperidone is extensively metabolized by CYP3A4
and CYP2D6 [42]. It is therefore recommended that the
dose be reduced by 50% when coadministered with potent
inhibitors of these cytochrome systems. There are no
adjustment recommendations in patients with hepatic or
renal impairment, however, Sedek et al., noted a doubling
of half-life in patients with renal impairment compared
with healthy controls (33.7 vs. 15 h; p < 0.05) [44, 47].
A pooled analysis of three RCTs in schizophrenia noted
most common adverse events of iloperidone were dizziness, headache, dry mouth, nausea, and insomnia [48, 49].
The rates of discontinuation due to adverse events were
not statistically different between iloperidone and placebo
(4.8% for both) and were lower than risperidone (6.2%)
and haloperidol (7.6%) [48, 49]. Iloperidone-treated
patients showed significantly low rates of akathisia compared with haloperidol and risperidone [49]. However,
iloperidone-treated patients demonstrated a significant
increase in weight of up to 2.1 kg during the 6-week intervention, which was greater than risperidone (+ 1.5 kg) and
placebo (− 0.3 kg) [49]. In addition, iloperidone-treated
patients had at least a mild increase in serum glucose [49].
There was a linear dose response with the mean increase
in serum glucose of 7.2 mg/dL [standard deviation (SD)
1.8–12.6] in the iloperidone 4–8 mg/day group versus
16.2 mg/dL (SD 3.6–27) in the 20–24 mg/day group [49].
The authors also observed a significant linear increase in
the QTcF interval on their ECG in the iloperidone-treated
arm (2.9 ms in the 4–8 mg/day dose group vs. 9.1 ms in
the 20–24 mg/day dose group) [49].
This review did not identify any ongoing or published
studies of iloperidone for the acute or maintenance phases
of treatment of either adult or late-life bipolar disorder, and
hence no clinical recommendations can be offered.

Asenapine is a newer-generation antipsychotic approved by
the FDA in 2009 for the treatment of schizophrenia, as well
as for the management of acute mania or mixed episodes
associated with bipolar I disorder. Its mechanism of action
includes being a potent antagonist at dopamine D2 and
serotonin 5-HT2A receptors [50]. It also binds to serotonin
5-HT1A, 5-HT2C, 5-HT6, 5-HT7, histamine H1 and noradrenergic α1 receptors [50]; however, it has negligible affinity
for muscarinic M
 1 receptors [50]. It also acts as a partial
agonist at 5-HT1A receptors [50], which could contribute to
its additional antianxiety effects. One study showed a low
incidence of orthostatic hypotension and dizziness despite
the potent antagonist effects of asenapine at noradrenergic
α1 receptors [50]. Asenapine is the only antipsychotic drug
that is available exclusively in sublingual form. Its bioavailability is approximately 35%, which reduces further if taken
with food or water [51]. Although the terminal half-life is
approximately 24 h, it is usually administered twice daily
because the limited surface area in the oral cavity may limit
the extent of drug absorption for high doses [51]. Asenapine
is primarily metabolized via glucuronidation by UGT1A4,
and undergoes oxidative metabolism by CYP1A2 [52]; however, smoking, which is known to induce CYP1A2, does
not appear to impact the metabolism of asenapine [52]. As
it is taken in a sublingual form, it is known to be rapidly
absorbed, and leads to at least mild to moderate somnolence. Such an effect is likely efficacious in the treatment
of agitation [52], a presenting feature of acute mania. The
manufacturer does not recommend dosage adjustments for
older adults, but a clinical trial in patients with schizophrenia found that the clearance of asenapine was inversely proportional to age. It was also found that elderly adults (aged
65–85 years) were exposed to 30% more drug than younger
adult patients [53]. However, despite the increased exposure,
short-term asenapine treatment was generally well tolerated
in elderly patients with psychosis during rapid dosage escalation [54].
We identified a 12-week, prospective, open-label study
designed to assess the efficacy and tolerability of adjunctive asenapine (n = 15, initiated at 5 mg/day and titrated as
tolerated) in a non-dementia older adult sample (≥ 60 years
of age) with suboptimal previous response to other bipolar
disorder treatments [53]. There was global improvement in
psychotic, manic, and depressive symptoms (p < 0.05) [53].
The most commonly reported adverse effects were gastrointestinal discomfort (n = 5, 33%), restlessness (n = 2, 13%),
tremors (n = 2, 13%), cognitive difficulties (n = 2, 13%),
and sluggishness (n = 2, 13%) [53]. It is worth mentioning
that asenapine is known to cause oral hypoesthesia [number
needed to harm (NNH) 20, 95% confidence interval (CI)
13–50] [54]. Additionally, cognitively impaired older bipolar

Author's Personal Copy
patients may not be able to follow the specific instructions
for its sublingual administration only.
While asenapine has a favorable pharmacological profile,
which could theoretically be of benefit in treating OABD,
the lack of any large-scale RCT data, and the reasonably
poor acceptability rate, limits the support for the clinical
utility of asenapine in OABD.

2.6 Paliperidone
Paliperidone was approved by the FDA in 2006 for the treatment of schizophrenia, and in 2009 for schizoaffective disorder. Its approved dose range for administration is 3–12 mg/
day [55]. It is the 9-hydroxy-risperidone metabolite of risperidone and therefore has a receptor affinity and adverse
effects profile similar to risperidone [55]. Both risperidone
and paliperidone have antagonistic activity at the α1, α2, D2,
H1, and 5-HT2A receptors [55]; however, paliperidone has
been reported to have lower affinity for α2, 5-HT2A, 5-HT1A,
and 5-HT1D compared with risperidone [55]. Adverse effects
reported as common to both agents include weight gain,
insulin resistance, poor blood glucose control and hyperprolactinemia [56]. A recent review suggests that all these
adverse effects are not clinically significant [56], while other
studies suggest that paliperidone causes a greater increase in
prolactin compared with its congener risperidone [57, 58].
Oral paliperidone is available as an extended-release (ER)
tablet that is administered once daily, which offers some
pharmacokinetic advantage over the twice-daily administration of risperidone [56]. Per the manufacturer, the shell
of the ER tablet does not deform as it moves through the
gastrointestinal tract [59]. It is suspected that this can cause
problems for patients with pre-existing inflammatory bowel
disease or pre-existing gastrointestinal tract narrowing,
although incidence rates for gastrointestinal obstruction
are unknown [59]. Paliperidone is cleared renally, and the
manufacturer recommends a dose of 3 mg once daily in
patients suffering mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min) [59]. The dose may be
increased to a maximum of 6 mg once daily based on clinical
response and tolerability [59]. For patients with moderate to
severe renal impairment (creatinine clearance ≥ 10 mL/min
to < 50 mL/min), the recommended initial dose is 1.5 mg
once daily, which may be increased to a maximum of 3 mg
once daily [59]. Similar dose adjustments are suggested for
the injectable form of paliperidone in patients with renal
impairment [59].
We found no randomized controlled or open-label trials
of paliperidone ER in late-life bipolar disorder; however,
we did find two trials of paliperidone in adult bipolar disorder samples. Berwaerts et al., 2011 studied paliperidone
in a randomized, placebo-controlled design as adjunctive
therapy to lithium or valproate in the treatment of acute
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mania (age 18–65 years). Eligible patients (n = 300) had a
mild to moderate manic syndrome, as evidenced by a YMRS
total score ≥ 20 [60]. Participants were randomly allocated
(1:1) to continue their mood stabilizer monotherapy or
receive flexibly administered paliperidone (3–12 mg/day)
as augmentation treatment for 6 weeks [60]. There was a
non-significant difference in change scores from baseline
to endpoint in the YMRS total score for augmentation with
paliperidone [− 14.3 (SD 10.0)] compared with ongoing
mood stabilizer monotherapy [− 13.2 (SD 10.9); p = 0.16]
[60]. The incidence of treatment-emergent adverse events
was higher with augmentation treatment (70%) than with
mood stabilizer monotherapy (54%) [60]. Insomnia was the
most commonly reported adverse event in both treatment
groups (11%) [60].
In another randomized, placebo-controlled study, oral
paliperidone ER was used as maintenance treatment in
patients with bipolar I disorder after resolution of the acute
manic phase [61]. Study participants included 766 patients
aged 18–65 years administered flexible-dose paliperidone
(3–12 mg/day) or olanzapine (5–20 mg/day) during a 3-week
acute treatment phase before entry into the maintenance
phase [61]. They found that the median time to recurrence of
any mood symptoms in the maintenance phase was 558 days
with paliperidone ER, and 283 days with placebo, while
there was lack of recurrence of mood symptoms on patients
taking olanzapine [61]. Overall, the time to recurrence of
any mood symptoms was significantly longer with paliperidone ER than placebo [p = 0.017; hazard ratio (placebo:
paliperidone ER; unweighted 95% CI): 1.43 (1.03; 1.98)]
[61]. Such a difference was found to be significant for preventing recurrence of manic symptoms, but interestingly not
for depressive symptoms [61].
The pharmacological profile of paliperidone ER offers
some theoretical safety benefit over risperidone in the treatment of bipolar disorder; however, this is not supported by
similar prevalence rates of adverse events with this agent.
Additionally, its role in acute and maintenance treatment of
adult bipolar treatment is weak, as per published RCT data.
Lastly, there are no ongoing or completed trials of this agent
in late-life bipolar disorder, and hence it cannot be recommended for routine use in the management of this disorder.

2.7 Aripiprazole
Aripiprazole was approved by the FDA in 2002 for the treatment of schizophrenia, in 2004 for acute manic and mixed
episodes, and in 2007 as an adjunct for major depressive
disorder [62]. Aripiprazole is marketed in doses ranging
from 2 to 30 mg/day, with a recommended starting oral dose
of 15 mg/day in schizophrenia and acute manic and mixed
episodes of bipolar [63]. In addition, in July 2017, Abilify
Maintena, an ER injectable suspension of aripiprazole, was
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approved by the FDA for maintenance monotherapy treatment of bipolar I disorder in adults [64].
The pharmacology of aripiprazole is somewhat unique in
being the first atypical antipsychotic with D
 2 partial agonist
activity [63]. It also has partial agonist activity at the 5 HT1A
receptors and antagonist activity at 5HT2A receptors [63].
Aripiprazole is well absorbed and administered once daily
due to its long half-life of 146 h [63]. It is known to undergo
hepatic metabolism via CYP2D6 and CYP3A4 to its active
metabolite dehydroaripiprazole [63]. Patients taking a strong
CYP3A4-inducing medication such as carbamazepine
should double the oral dose of aripiprazole over 1–2 weeks
[63]. Patients who are slow CYP2D6 metabolizers, or taking a CYP2D6 or CYP3A4 inhibitor, may require half the
usual dose, while patients who are taking concomitant strong
CYP2D6 and CYP3A4 inhibitors may require one-quarter
of the usual dose of aripiprazole compared with patients not
impacted by CYP2D6 or 3A4 activity [63].
In the elderly, it is recommended to start on a lower dose
and titrate slowly. As a result of partial D2 agonism, and less
D2 blockade, aripiprazole has been found to have a lower
incidence of EPS compared with some antipsychotics [65].
Furthermore, it offers the least risk of hyperprolactinemia
[65]. Additionally, it seems to have lesser sedative potential
than other antipsychotics [65]. Lastly, a large comparative
efficacy and tolerability meta-analysis of 15 antipsychotics
used in the treatment of schizophrenia showed that aripiprazole caused at least a mild grade of weight gain compared
with other antipsychotics, and caused significant weight
gain compared with placebo (standardized mean difference
− 0.17, 95% CI − 0.28 to − 0.05; a negative value suggests
more weight gain compared with placebo) [65].
The recent Canadian Network for Mood and Anxiety
Treatments (CANMAT) treatment guidelines indicated that
aripiprazole monotherapy can be used as first-line therapy
for the treatment of acute mania, and in maintenance therapy
of adult bipolar disorder [4]. These guidelines continue to
recommend that this agent not be used as a monotherapy
agent in acute depression [4]. Based on the available evidence, these guidelines also suggest a level 4 recommendation for the use of aripiprazole in the treatment of OABD
based on a single open-label study. This particular study
was a 12-week prospective trial of add-on oral aripiprazole
in 20 adults aged 50 years and older in the acute treatment
of bipolar disorder [66]. Patients were administered oral
aripiprazole initiated at doses of 5 mg/day, and the dose
was increased as tolerated. Participants had a significant
reduction in their mean depression scores on the Hamilton Depression Scale (HAM-D), from a baseline score of
13.8 (SD 6.6) to 6.1 (SD 3.71) [p < 0.001] in the 12-week
period [66]. Additionally, there was an improvement in
mania symptoms on the YMRS; baseline scores of 8.6 (SD
5.66) fell to 3.9 (SD 2.05) [p < 0.03] [66]. There were also

significant improvements in functional status as measured
by the Global Assessment Scale (GAS; p < 0.001) [66].
The mean ± SD daily dose of aripiprazole used in this trial
was 10.26 mg/day (SD 4.9) [66]. Authors commented that,
overall, the drug was adequately tolerated in this older adult
population [66].
In the unpublished literature, we identified a 12-week
open-label trial of aripiprazole in the treatment of refractory bipolar depression. This study was initiated in 2004 and
completed in 2009. Patients were recruited if they were aged
between 18 and 75 years. No further details are currently
available in the public domain, likely because the study was
withdrawn (NCT00223496). Another multicenter clinical
trial investigated the safety and efficacy of extended administration of oral aripiprazole in combination with a mood
stabilizer for the maintenance treatment of patients with
bipolar disorder experiencing a manic or mixed episode.
Participants were administered open-label 12, 24, or 30 mg/
day aripiprazole for 154 days. Subjects were also coadministered a mood stabilizer. Of the 55 recruited patients, three
were aged ≤ 18 years and the rest were of adult age range
(18–65 years of age, n = 52). Participants’ mania symptoms
were monitored using the YMRS and CGI–Bipolar Version
(CGI-BP) scales. The mean fall on the YMRS was − 18.3
(SD 12.71), while on the CGI-BP, the mean fall was −2.4
(SD 1.76) [NCT00606320]. No statistical tests of comparison were published.
Aripiprazole has been on the market for the longest
period of time compared with the rest of the reviewed atypical antipsychotics. While it offers clinically effective mood
augmenting response with venlafaxine in the treatment of
late-life unipolar depression [67], its safety and efficacy has
not been established in OABD. With the lack of good-quality RCT data in OABD, this agent cannot be recommended
for routine use.

3 Conclusions
As the world’s population ages, it is expected that the number of patients being treated for bipolar disorder in later
life will increase in both primary care and secondary care
hospital settings. Given the complex needs of this group of
patients, newer treatment options are sorely needed. Lithium and valproic acid remain the treatment of choice for
the management of OABD based on accumulated clinical
experience and confirmed by recent evidence [19]. Over the
last 15 years, at least seven new atypical antipsychotics have
come onto the market for the treatment of schizophrenia;
however, only a few have gained marketing approval for
the additional indication of treatment of bipolar disorder.
Our review of these seven newer atypical antipsychotics
found no RCT studies of any of these agents in any phase of
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OABD. On expanding our scope of this review, we included
two post hoc studies of lurasidone, and found a reasonable
efficacy profile of this agent in the acute and maintenance
treatment of this illness, and hence lurasidone can be recommended for routine use. Further cost–benefit analysis of this
agent remains to be investigated. Initial data from open-label
studies also shows promise for the use of oral asenapine and
aripiprazole as adjunctive therapy, but such findings need to
be confirmed in RCTs. There are no data to support the use
brexpiprazole, cariprazine, iloperidone, and paliperidone in
the treatment of OABD. Future studies are sorely needed
in this area.
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